Drugs / Acaroid
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00540631 | Oct 2007 → Aug 2010 | rhinitis | Allergopharma GmbH & Co. KG | Completed | No outcome recorded |
| Phase 3 | NCT00263640 | May 2005 → Apr 2009 | allergic asthma | Allergopharma GmbH & Co. KG | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Acaroid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00263640 ↗ |
| Modality | Protein / enzyme biologic | “aluminium hydroxide-adsorbed allergoid preparation” NCT00540631 ↗ |
| Route | Subcutaneous | “was given as a subcutaneous injections of increasing doses” NCT00263640 ↗ |